Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 2

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 2
---
57,193,356.

As of October 3, 2024, the number of shares outstanding of the registrant’s
common stock, par value $0.0001 per share (the “Common Stock”) was 156,193,912.

<div align='center'>DOCUMENTS INCORPORATED BY REFERENCE</div>

The information required by Items 10, 11, 12, 13 and 14 of Part III of this Report is incorporated by reference to the registrant’s Amendment No. 1 on Form 10-K/A that was filed with the Securities and Exchange Commission on October 28, 2024.

<div align='center'>EXPLANATORY NOTE</div>

Renovaro Inc. (the “Company”, “we”, “our”, or “us”) is filing this Amendment No. 2 to its Annual Report on Form 10-K/A (this “Amendment”) to amend its Annual
Report on Form 10-K for the year ended June 30, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on
October 10, 2024, as amended by that Annual Report on Form 10-K/A filed with the SEC on October 28, 2024 (the “2024 Form 10-K”)
to (i) restate its financial statements as of and for the year ended June 30, 2024, which should no longer be relied on and are being
restated herein; and (ii) describe the restatement and its impact on previously reported amounts.

We are filing this Amendment
to amend and restate the 2024 Form 10-K with modifications as necessary to reflect these restatements.

Background of Restatement

On February 18, 2025, the Audit
Committee (the “Audit Committee”) of the Board of Directors of the Company, based on the recommendation of the Company’s
management, and after consultation with the Company’s independent registered public accounting firm, concluded that the Company’s
previously consolidated financial statements for the year ended June 30, 2024 contained a material misstatement related to the exercising
of certain warrants which impacted the change in fair value of the contingent consideration liability during February 2024. Accordingly,
those financial statements should no longer be relied upon. Similarly, related reports filed with the Securities Exchange Commission (the
“SEC”), earnings releases, press releases, shareholder communications, investor presentations or other communications describing
relevant portions